Fleur S. Van Dijk

Dr. Fleur S. Van Dijk


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FDFleur S. Van Dijk
Fleur S. Van Dijk
OSOliver Semler
Oliver Semler
JEJulia Etich
Julia Etich
AKAnna Köhler
Anna Köhler
JJJuan A. Jimenez-Estrada
Juan A. Jimenez-Estrada
DMDimitra Micha
Dimitra Micha

29 May 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CAC. Angwin
C. Angwin
NGN. Ghali
N. Ghali
DBD. Baker
D. Baker
ABA.F. Brady
A.F. Brady
FPF.M. Pope
F.M. Pope
FDFleur S. Van Dijk
Fleur S. Van Dijk

2 October 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
IKInes Kapferer-Seebacher
Ines Kapferer-Seebacher
EOElizabeth Oakley-Hannibal
Elizabeth Oakley-Hannibal
ULUlrike Lepperdinger
Ulrike Lepperdinger
DJDiana Johnson
Diana Johnson
NGNeeti Ghali
Neeti Ghali
FDFleur S. Van Dijk
Fleur S. Van Dijk

23 June 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
CGClaire Green
Claire Green
NGNeeti Ghali
Neeti Ghali
RARhoda Akilapa
Rhoda Akilapa
CAChloe Angwin
Chloe Angwin
DBDuncan Baker
Duncan Baker
FDFleur S. Van Dijk
Fleur S. Van Dijk

24 February 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SASandy Ayoub
Sandy Ayoub
NGNeeti Ghali
Neeti Ghali
CAChloe Angwin
Chloe Angwin
DBDuncan Baker
Duncan Baker
SBStella Baffini
Stella Baffini
FDFleur S. Van Dijk
Fleur S. Van Dijk

3 January 2020 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
AHArjan G. J. Harsevoort
Arjan G. J. Harsevoort
KGKoert Gooijer
Koert Gooijer
FDFleur S. Van Dijk
Fleur S. Van Dijk
DGDaniëlle A. F. M. van der Grijn
Daniëlle A. F. M. van der Grijn
AFAnton A. M. Franken
Anton A. M. Franken
GJGuus J. M. Janus
Guus J. M. Janus
Background: Osteogenesis Imperfecta (OI) is characterized by bone fragility, and features such as blue sclerae, dentinogenesis imperfecta, hearing loss, ligamentous laxity and short stature can be present. It has long been assumed that the functional ability and quality of life of patients with OI depends primarily on the severity of skeletal deformities. However, fatigue is often mentioned in clinic by patients with all types of OI as an important modifier of their quality of life and does not always seem to be related to their functional ability. The aim of this study is to investigate whether adults with Osteogenesis Imperfecta are significantly more fatigued than the normal population. Methods: The Fatigue Severity Scale (FSS) was distributed by mobile phone application among 151 adult patients with different OI types. Results of the FSS in the OI group were compared with two control populations from America (n = 20) and the Netherlands (n = 113). Results: Ninety-nine patients (OI type 1 (n = 72), OI type 3 (n = 13), OI type 4 (n = 14) completed the FSS questionnaire. The mean FSS score of this cohort was 4.4 and significantly higher than the control populations (2.3/2.9). 65% of our cohort reported at least moderate fatigue compared with 2 control populations from America and the Netherlands. Conclusion: Fatigue in patients with OI is a frequently encountered problem in our expert clinic but research into this topic is sparse. This pilot study is the largest study to date investigating fatigue in patients with OI and results have been compared with two control groups. The mean FSS score of 4.4 in the OI group indicates that people with OI are generally significantly more fatigued than the control population. Further evaluation of fatigue and its influencers in a larger group of OI patients is important for future management.